Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML

This publication has 46 references indexed in Scilit:

• Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
  New England Journal of Medicine, 2002
• Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment
  Blood, 2002
• Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
  New England Journal of Medicine, 2002
• Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
  Science, 2001
• Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome
  New England Journal of Medicine, 2001
• Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase
  Science, 2000
• Inhibition of the ABL Kinase Activity Blocks the Proliferation of BCR/ABL+Leukemic Cells and Induces Apoptosis
  Blood Cells, Molecules, and Diseases, 1997
• Mice homozygous for the ablm1 mutation show poor viability and depletion of selected B and T cell populations
  Cell, 1991
• Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene
  Cell, 1991
• Psychogenic amenorrhea: Diagnosis by exclusion
  Psychosomatics, 1979